(Q37451135)

20 August 2017

1 reference

title

Mechanisms of resistance to EGFR inhibitors in head and neck cancer (English)

1 reference

20 August 2017

Jonathan B Cooper

1

1 reference

PubMed ID

19378324

20 August 2017

Ezra Eddy Wyssam Cohen

series ordinal

2

1 reference

20 August 2017

1 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

31

1 reference

20 August 2017

1086-1094

1 reference

20 August 2017

8

1 reference

High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India

20 August 2017

1 reference

Oncogene amplification in squamous cell carcinoma of the oral cavity.

21 January 2018

1 reference

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

7 January 2021

Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region

1 reference

7 January 2021

EGF-ERBB signalling: towards the systems level

1 reference

7 January 2021

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

7 January 2021

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

1 reference

7 January 2021

Targeting epidermal growth factor receptor in head and neck cancer

1 reference

7 January 2021

Chemoradiotherapy: emerging treatment improvement strategies

1 reference

7 January 2021

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

1 reference

7 January 2021

TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo

1 reference

7 January 2021

Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter

1 reference

7 January 2021

Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

1 reference

7 January 2021

Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro

1 reference

7 January 2021

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

1 reference

7 January 2021

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

1 reference

7 January 2021

Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

7 January 2021

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

7 January 2021

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

1 reference

7 January 2021

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

1 reference

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

7 January 2021

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

7 January 2021

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

7 January 2021

A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

1 reference

7 January 2021

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

1 reference

7 January 2021

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.

1 reference

7 January 2021

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

7 January 2021

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

1 reference

7 January 2021

Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

1 reference

7 January 2021

Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib

1 reference

7 January 2021

Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines

1 reference

7 January 2021

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

7 January 2021

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

1 reference

7 January 2021

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

1 reference

7 January 2021

Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.

1 reference

7 January 2021

Signaling by distinct classes of phosphoinositide 3-kinases

1 reference

7 January 2021

Mechanism of activation of protein kinase B by insulin and IGF-1

1 reference

7 January 2021

Oncogenic kinase signalling

1 reference

7 January 2021

Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells

1 reference

7 January 2021

Current overview of the role of Akt in cancer studies via applied immunohistochemistry

1 reference

7 January 2021

AKT/PKB signaling: navigating downstream

1 reference

7 January 2021

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

1 reference

7 January 2021

The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase

1 reference

7 January 2021

Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2

1 reference

7 January 2021

p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity

1 reference

7 January 2021

SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival

1 reference

7 January 2021

Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle

1 reference

7 January 2021

5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells

1 reference

7 January 2021

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

1 reference

7 January 2021

PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells

1 reference

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

7 January 2021

The biology and clinical relevance of the PTEN tumor suppressor pathway

1 reference

7 January 2021

Why is PTEN an important tumor suppressor?

1 reference

7 January 2021

PTEN: one gene, many syndromes

1 reference

7 January 2021

The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation

1 reference

7 January 2021

Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex

1 reference

7 January 2021

Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate

1 reference

7 January 2021

PTEN mutations in gliomas and glioneuronal tumors.

1 reference

7 January 2021

PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas.

1 reference

7 January 2021

PTEN signaling pathways in melanoma

1 reference

7 January 2021

Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.

1 reference

7 January 2021

Expression of PTEN protein in patients with laryngeal squamous cell carcinoma

1 reference

7 January 2021

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1 reference

7 January 2021

Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors

1 reference

7 January 2021

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

7 January 2021

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

7 January 2021

PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression

1 reference

7 January 2021

Identifiers

DOI

10.1002/HED.21109

1 reference

release_tqmrw3mdcjcutkvelqishxqs7q

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tqmrw3mdcjcutkvelqishxqs7q

24 November 2022

mapped directly with Wikidata item

PubMed ID

19378324

1 reference

PubMed ID

19378324